Nonalcoholic Steatohepatitis Linked to Increased MortalityCMENonalcoholic steatohepatitis increases the risk for death vs the general population, and liver disease is the third most common cause of death in patients with nonalcoholic fatty liver disease.
MedscapeCME Clinical Briefs, February 2010
Optimizing the Safety of Biologic Therapy for IBDCMEKnowledge about the potential adverse effects of biologic agents with appropriate pretreatment strategies and follow-up and monitoring will allow optimal outcomes of treatment for patients with IBD.
Nature Reviews Gastroenterology & Hepatology, February 2010
NCCN - MedscapeCME Metastatic Colorectal Cancer Tumor BoardCME/CEIn this video roundtable, Drs. Alan Venook, Mary Mulcahy, and Michael Choti illustrate the process of treatment decision making as they "think through" 2 complex patient cases.
Ongoing Challenges in Hepatitis B: Addressing Real-World IssuesCMETune in to this video roundtable discussion to hear Drs. Poordad, Saab, and Reau review the approved antiviral therapies for first-line treatment of HBV and factors contributing to underdiagnosis.
Exploring the Role of Adjuvant Therapy in GIST: Are We There Yet? CMEDoctors Jonathan Fletcher, Margaret von Mehren, and Ronald De Matteo discuss advances in metastatic disease that have pointed the way toward improved treatment options in the adjuvant setting for GIST.